This Vaccine May Be Our Best Chance To Eradicate AIDS

This Vaccine May Be Our Best Chance To Eradicate AIDS

Spanish researchers have completed the first human trial of a new vaccine against HIV. It has been successful in 90 per cent of the HIV-free volunteers during phase I testing. It brings great hope to eradicate this plague.

The team lead by Dr Mariano Esteban, a researcher at the Spanish National Research Council’s Biotechnology National Centre, has been working on this method since 1999. His team is using an attenuated virus called the MVA-B, a variation of the Modified Ankara Vaccinia, which was previously used to eradicate smallpox and forms the base of other vaccines. The B refers to the HIV-B, the most common HIV subtype in Europe.

Dr Esteban’s team inserted the HIV genes Gag, Pol, Nef and Env in MVA-B’s genetic sequence. In 2008, they tried the resulting HIV nuke on mice and monkeys. It was a complete success.

Successful human test

The first human test, which was published in Vaccine and Journal of Virology, injected the vaccine in 24 of 30 HIV-free volunteers. Six volunteers were treated with a placebo vaccine — they didn’t experience any effect. But 90 per cent of the treated subjects developed a very strong immunological response against the HIV virus. 85 per cent kept this reaction for at least one year, which is really good news.

According to the results, there were no significant secondary effects in any of the patiences, which was one of the major objectives of to be tested in this clinical trial.


Despite the success, Dr Esteban is cautious.

[T] he treatment has only been tested on 30 volunteers and, while [the vaccine]provokes a powerful response in most of the cases, it’s still to soon if the resulting defence would be effective against an actual [HIV]infection.

The team will now start another phase I trial, injecting the vaccine in HIV-infected people. The objective of this trial is to test the therapeutical effect of the vaccine in these patients.

According to Dr Esteban, “in principle, the immunological profile of MVA-B satisfies the requirements for a promising vaccine against the HIV, like the creation of antibodies and the activation of key cells in the defence against the virus.” Sadly, it is still far away from commercialisation: they need to test this on phase II and III trials, injecting vaccinated volunteers with the actual HIV virus on a larger scale.

Hopefully, one day this one will nail that HIV bastard down. [CSIC]